What is the evidence that early use of biologic agents improves long‑term remission rates in pediatric UC compared with a step‑up strategy
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
no head-to-head trial has established that upfront biologics improve long-term remission over step-up therapy in pediatric ulcerative colitis; no studies were identified comparing upfront biologic-based therapy versus gradual step-up in moderate-to-severe UC 1, and the top-down approach has not been studied in UC as it has in Crohn's disease 2. Evidence for early biologic benefit is strong in Crohn's disease but is not demonstrated for UC 3. 1,3–5
What is known: - No studies were identified comparing upfront biologic-based therapy versus gradual step-up (biologic only after 5-ASA failure) in moderate-severe UC. 1 - Early biologic treatment significantly improved remission and reduced surgery in luminal Crohn's disease, but this benefit was demonstrated in Crohn's, not UC. 3 - A pediatric UC cohort found the 2-year colectomy probability fell from 14% to 3% across eras when infliximab and thiopurines were introduced earlier, alongside other practice changes. 4 - A nationwide epi-IIRN study reported that colectomy rates did not decrease in paediatric- and adult-onset UC during the biologics era. 5
What is unknown / caveats: - Single-center cohort links earlier infliximab/thiopurine to lower colectomy 4, while a nationwide study found no decrease in colectomy in the biologics era 5 - Cohort data are retrospective/registry-based and confounded by concurrent changes (earlier 5-ASA, drug monitoring) - Long-term remission specifically was not the endpoint in the cited pediatric studies - The direct comparison of early biologics versus step-up on long-term remission in pediatric UC has not been done.
## References
1. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, AGA Institute Clinical Guidelines C. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020. PMID: 31945371.
2. Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg. 2010;23:227-38. PMID: 22131893.
3. [No authors listed]. Early Biologic Treatment for Inflammatory Bowel Disease: Drugs. 2024. PMID: 39652700.
4. Bolia R, Rajanayagam J, Hardikar W, Alex G. Impact of Changing Treatment Strategies on Outcomes in Pediatric Ulcerative Colitis. Inflamm Bowel Dis. 2019;25:1838-1844. PMID: 31002341.
5. Wine E, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M, Gianolio L, Gordon H, Hojsak I, Hudson AS, Hussey S, van Limbergen J, Miele E, Norsa L, Olén O, Pellino G, van Rheenen P, de Ridder L, Russell RK, Shouval DS, Trindade E, Turner D, Wilson DC, Yerushalmy Feler A, Assa A. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. J Pediatr Gastroenterol Nutr. 2025;81(3):765-815. PMID: 40677018.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
---
_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._
Reviewer notes